Roles
- Professor of Clinical Medicine
-
Biography
Jonathan Schatz, M.D., is a Professor of Clinical Medicine and Chair of the CMSR Scientific Advisory Committee in the Division of Hematology at the University of Miami Miller School of Medicine. He began his career as a journalist after graduating from the University of Wisconsin-Madison before pursuing science and medicine. After premedical studies at Brandeis University, he earned his medical degree from the University of Chicago Pritzker School of Medicine, conducting research on blood cancer–related genes in the laboratory of Dr. Harinder Singh. He completed an internal medicine residency at University of Chicago Hospitals and a hematology-oncology fellowship at Memorial Sloan Kettering Cancer Center, where he focused on lymphoma research.
Dr. Schatz began his faculty career at the University of Arizona in 2012, establishing an independent laboratory studying treatment resistance and novel therapies for lymphomas while maintaining an active clinical practice. In 2015, he joined Sylvester Comprehensive Cancer Center at the University of Miami, where his research focuses on overcoming resistance mechanisms to targeted therapies. His work identified PIM kinase–mediated maintenance of cap-dependent translation as a resistance mechanism to mTOR inhibitors and has led to novel therapeutic strategies, including targeting the DEAD-box RNA helicase eIF4A with rocaglates now entering clinical trials.
The Schatz laboratory focuses on diffuse large B-cell lymphoma (DLBCL), exploring novel combination therapies, mechanisms of recurrent oncogenes such as BCL10, and druggable dependencies including Cyclin-G Associated Kinase (GAK). The lab also investigates tumor-intrinsic factors influencing responses to cellular immunotherapies, including CAR T-cell therapies, with ongoing efforts to translate these findings into clinical applications. -
Education & Training
Education
Post Graduate Training
Licensures and Certifications
-
Honors & Awards
-
Research Interests
Non-Hodgkin lymphoma, Translation, Cancer Immunotherapy, Drug Discovery -
Publications
Disclaimer: Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.Professional Activities
Articles & News
Sylvester Comprehensive Cancer Center Researchers Discover Why Some Lymphomas Resist CAR T-cell Treatment
Exploring the Biology of Lymphoma to Identify New Drug Targets
How Patients’ Own Cells are Treating — and Sometimes Curing — Their Cancer
Disclaimer:
Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Clinical Trials
Viewing 0 of 5 clinical trials.
-
This study is being done to find the best dose, possible benefits, and/or side effects of duvelisib when taken in combination with nivolumab, in treating patients with advanced mycosis fungoides and Sezary syndrome. Giving duvelisib in combination with nivolumab may work better than giving each of these drugs individually, or treating with the usual approach in patients with mycosis fungoides and Sezary syndrome.
- Principal Investigator: Jonathan Schatz
- Study Phase: Phase I
- Enrollment Status: Not Accepting
-
Progression-free survival (PFS) of soquelitinib compared to standard of care (SOC) per Independent Review Committee (IRC) assessment Objective response rate (ORR) of soquelitinib compared to SOC
- Principal Investigator: Jonathan Schatz
- Study Phase: Phase III
- Enrollment Status: Open
-
Phase II Multicenter Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
- Principal Investigator: Jonathan Schatz
- Study Phase: Phase 2
- Enrollment Status: Not Accepting
-
Phase I Multicenter Study of Ruxolitinib and Duvelisib in Relapsed or Refractory T- or NK-Cell Lymphomas
- Principal Investigator: Jonathan Schatz
- Study Phase: Phase 1
- Enrollment Status: Not Accepting
-
A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell Lymphomas
- Principal Investigator: Jonathan Schatz
- Study Phase: Phase 2
- Enrollment Status: Open
